

*VAAM Industry-Academia Panel, 15.01.2026*

Dr. Rüdiger Trojok, [Medea Biopharma GmbH](#), Ludwigshafen

### "Industrializing Phage Therapy"

Antimicrobial resistance is driving demand for natural, residue-free antibacterial solutions, but phage products have so far remained fragmented, artisanal, and difficult to scale. The core bottleneck is the lack of continuously growing, high-quality phage biobanks combined with cost-efficient, GMP-ready production. MEDEA Biopharma GmbH solves this by building the industrial backbone for phage-based products. Its automation- and AI-driven platform (Velion) enables rapid, scalable discovery, selection, and banking of high-performance phages, while its bioreactor-based GMP scale-out manufacturing delivers phage APIs at high quality and low cost. This allows both standardized industrial products and personalized applications from the same infrastructure. Positioned upstream as a **Phage Active Ingredient Provider**, MEDEA supplies GMP-grade phage ingredients to partners in pharma, nutrition, food, and agriculture, who handle formulation and market access. This scalable, partner-centric model differentiates MEDEA from therapy-focused competitors and positions it as the foundational platform for the next generation of antibacterial innovation.